Sage Journals: Discover world-class research

Abstract

ΔNp63 (henceforth simply p40) is a squamous/basal-type biomarker corresponding to nontransactivating (non-TA) isoforms of p63 gene. Its prospective relevance as driver biomarker in lung cancer has not yet been thoroughly investigated. In all, 72 adenocarcinomas (ADs), 27 squamous cell carcinomas (SQCs), 13 pleomorphic carcinomas (PLCs), 10 small-cell lung carcinomas (SCLCs), 5 large-cell neuroendocrine carcinomas (LCNECs), 5 adenosquamous carcinomas (ADSQCs), 3 large-cell carcinomas with basaloid features (B-LCC), 2 carcinoids, 2 carcinosarcomas (CS), 2 salivary-gland type tumors (SGTTs) of the lung, and 5 pleural malignant epithelioid mesotheliomas (MEMs) were prospectively diagnosed by morphology and verified by immunohistochemistry for p40, p63, and thyroid transcription factor 1 (TTF1). Histological scores (HS) were devised by multiplying the percentage of immunoreactive cells (0 to 100%) by immunostaining intensity (low = 1 vs strong = 2, according to internal controls). There was a nonrandom distribution of p40 across the diverse tumor groups and cell differentiation lineages, with p40-HS > 100 closely paralleling squamous or myoepithelial carcinomas (SQC, B-LCC, SQC-containing PLC, ADSQC with predominant SQC, SGTT), and p40-HS ≤ 10 pinpointing AD, AD-containing PLC, or CS and neuroendocrine (NE) tumors. At variance, p63-HS was significantly higher than p40 in AD (P < .0001) and NE tumors (P = .0156), with positive predictive value being 83% and 95% and overall accuracy being 95% and 99%, respectively. Also, TTF1 was shared by gland-differentiated and NE tumors. MEM cases were always negative for all biomarkers. The HS-guided assessment of p40 allowed an effective orientation among thoracic malignancies at the level of individual tumor patients thereby contributing to prospectively realize a driver, holistic approach to cancer characterization.

Keywords

lung cancer p40 p63 TTF1 immunohistochemistry diagnosis

Get full access to this article

View all access options for this article.

References

Pao

Girard

. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.

Kratz

Van Den Eeden

. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012;379:823-832.

Pelosi

Pasini

Olsen Stenholm

. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198:100-109.

Hibi

Trink

Patturajan

. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000;97:5462-5467.

Wang

Gil

Kaufman

. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002;33:921-926.

Rossi

Pelosi

Graziano

Barbareschi

Papotti

. A reevaluation of the clinical significance of histological subtyping of non–small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-218.

Rossi

Papotti

Barbareschi

Graziano

Pelosi

. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009;27:e141-142.

Monica

Ceppi

Righi

. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22: 709-717.

Righi

Graziano

Fornari

. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.

10.

Bishop

Teruya-Feldstein

Westra

. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.

11.

Pelosi

Fabbri

Bianchi

. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012;7:281-290.

12.

Rekhtman

Ang

Sima

Travis

Moreira

. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24:1348-1359.

13.

Pelosi

Rossi

Bianchi

. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011;6:1039-1049.

14.

Hibi

Nakayama

Taguchi

. AIS overexpression in advanced esophageal cancer. Clin Cancer Res. 2001;7:469-472.

15.

Okuyama

Ogawa

Nagoshi

. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene. 2007;26:4478-4488.

16.

Yang

Kaghad

Wang

. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.

17.

Yang

Schweitzer

Sun

. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714-718.

18.

Chilosi

Poletti

Murer

. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002;82:1335-1345.

19.

Morbini

Inghilleri

Campo

. Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis. Pathol Res Pract. 2011;207:559-567.

20.

Romano

Ortt

Birkaya

Smalley

Sinha

. An active role of the ΔN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009;4:e5623.

21.

King

Ponnamperuma

Gerdes

. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis. 2006;27:53-63.

22.

Romano

Smalley

Magraw

. ΔNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012;139:772-782.

23.

Nekulova

Holcakova

Coates

Vojtesek

. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16:296-327.

24.

Karni-Schmidt

Castillo-Martin

Shen

. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 2011;178:1350-1360.

25.

Yang

Yan

. ΔNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011;71:3688-700.

26.

Saintigny

El-Naggar

Papadimitrakopoulou

. ΔNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009;15:6284-6291.

27.

Stelow

Bellizzi

Taneja

. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32:828-834.

28.

Boldrup

Coates

Nylander

. ΔNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol. 2009;218:428-436.

29.

Rekhtman

Paik

Arcila

. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18:1167-1176.

30.

Uramoto

Yamada

Hanagiri

. Immunohistochemical staining with ΔNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res. 2010;30:4717-4720.

31.

Pelosi

Sonzogni

Papotti

. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol. 2010;23:396A-415A.

32.

Pelosi

Fraggetta

Pasini

. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell lung carcinomas of the lung. Am J Surg Pathol. 2001;25:363-372.

33.

Yatabe

. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010;29:23-36.

34.

Yatabe

Mitsudomi

Takahashi

. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-773.

35.

Travis

Brambilla

Muller-Hermelink

Harris

. Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.

36.

Travis

Brambilla

Noguchi

. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.

37.

Sobin

Gospodarowicz

Wittekind

. TNM Classification of Malignant Tumours. New York, NY: Wiley-Blackwell; 2010.

38.

Sica

Yoshizawa

Sima

. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34:1155-1162.

39.

Pelosi

Melotti

Cavazza

. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Anticancer Res. 2012;32:1463-1473.

40.

Nonaka

. A study of Δnp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012;36:895-899.

41.

Barbareschi

Cantaloni

Del Vescovo

. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011;136:773-782.

42.

Mukhopadhyay

Katzenstein

. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, Napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.

43.

Terry

Leung

Laskin

. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34:1805-1811.

44.

Pelosi

Sonzogni

De Pas

. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18:103-120.

45.

Pardo

Martinez-Penuela

Sola

. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol. 2009;17:383-392.

46.

Molina

Aubry

Lewis

. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007;110:2253-2259.

47.

Takeuchi

Tomida

Yatabe

. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679-1688.

48.

Lo Iacono

Monica

Saviozzi

. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol. 2011;6:473-481.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.01 MB

0.04 MB

ΔNp63 (p40) Distribution Inside Lung Cancer

Abstract

Keywords

Get full access to this article

References

Supplementary Material